Thursday, May 31, 2007

Cardiac Safety of Avandia® (rosiglitazone maleate)

From Health Canada:
GlaxoSmithKline Inc (GSK), in conjunction with Health Canada, would like to address public concerns about the safety of Avandia®.

An article recently published in the New England Journal of Medicine (NEJM) has raised concern about an increased risk of myocardial infarction (heart attack) and cardiovascular death in patients with type 2 diabetes treated with Avandia®. This article was based on a review of 42 clinical studies. The conclusions reached require confirmation. Further investigation of these results is underway and more information will be communicated when available.
For the public

No comments: